lenalidomide has been researched along with levoleucovorin in 2 studies
| Studies (lenalidomide) | Trials (lenalidomide) | Recent Studies (post-2010) (lenalidomide) | Studies (levoleucovorin) | Trials (levoleucovorin) | Recent Studies (post-2010) (levoleucovorin) |
|---|---|---|---|---|---|
| 3,532 | 725 | 2,850 | 10,988 | 3,248 | 3,796 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Falchook, G; Fu, S; Hong, DS; Naing, A; Piha-Paul, S; Said, R; Tsimberidou, AM; Wheler, JJ; Ye, Y | 1 |
| Bertram, S; Dührsen, U; Ganser, A; Hüttmann, A; Ibach, S; Kroschinsky, F; Tometten, M | 1 |
2 trial(s) available for lenalidomide and levoleucovorin
| Article | Year |
|---|---|
Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Lenalidomide; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Organoplatinum Compounds; Survival Rate; Thalidomide; Treatment Outcome | 2016 |
Phase I/II trial of lenalidomide, methotrexate, leucovorin, cytarabine, and rituximab (LeMLAR) in relapsed or refractory diffuse large B cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Lenalidomide; Leucovorin; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Rituximab; Survival Analysis | 2021 |